Pieris Pharmaceuticals, Inc. (PIRS)

Oncology Corporate Profile

Stock Performance

5.2500
-0.0300

3 Month Stock History Chart

HQ Location

255 State Street
Boston, MA 2109

Company Description

Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumour micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia.

Website: http://www.pieris.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PRS-343CD137/HER2 inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.pieris.com

Recent News Headlines

8/21/2017 06:22 am

8/21/2017 06:22 am

8/21/2017 06:22 am

8/10/2017 06:19 pm

8/10/2017 06:19 am

8/9/2017 06:19 pm

8/9/2017 06:19 pm

8/9/2017 06:19 pm

8/9/2017 12:19 pm

8/9/2017 12:19 pm

7/12/2017 06:19 am

7/12/2017 06:19 am

7/12/2017 06:19 am

7/5/2017 12:21 pm

7/5/2017 12:21 pm

7/4/2017 12:19 pm

6/30/2017 12:19 pm

6/28/2017 12:20 pm

6/27/2017 06:19 am

6/4/2017 12:19 am

6/1/2017 12:19 pm

5/28/2017 06:18 am

5/10/2017 12:18 pm

5/4/2017 06:18 am

5/3/2017 06:18 am